A multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase II trial to investigate the efficacy and safety of 30 mcg and 100 mcg AS902330 given as one cycle of three intra-articular knee injections once a week for three weeks as an adjunct treatment to patients following microfracture surgery for cartilage injury of the knee.
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Sprifermin (Primary)
- Indications Cartilage disorders
- Focus Therapeutic Use
- Sponsors Merck KGaA
- 26 Sep 2014 New trial record